Cargando…

GABAergic but not Antidepressant Medications Increase Risk for Clostridioides difficile Infection in a National Cohort of Veterans

BACKGROUND: Clostridioides difficile infection (CDI) is primarily mediated by alterations in the host gut ecosystem. While antibiotic use is the primary risk factor for CDI, other medications that modulate the gut ecosystem, particularly those targeting the gut–brain axis, could impact CDI risk. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lalani, Falak, Young, Eric H, Panchal, Rupesh M, Reveles, Kelly R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486948/ https://www.ncbi.nlm.nih.gov/pubmed/32939356 http://dx.doi.org/10.1093/ofid/ofaa353

Ejemplares similares

80. Opioid Analgesics Are Associated with Increased Clostridioides difficile Infection Risk in a National Cohort of Veterans
por: Young, Eric H, et al.
Publicado: (2019)

Prevalence and Health Outcomes of Clostridioides difficile Infection During the Coronavirus Disease 2019 Pandemic in a National Sample of United States Hospital Systems
por: Reveles, Kelly R, et al.
Publicado: (2022)

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

A possible association between statin use and improved Clostridioides difficile infection mortality in veterans
por: Argamany, Jacqueline R., et al.
Publicado: (2019)

758. Increased Prevalence of Clostridioides difficile Infection During the COVID-19 Pandemic Among Hospitalized Veterans in South Texas, USA
por: Young, Eric H, et al.
Publicado: (2021)

The Clinical Burden of Clostridioides difficile in Ontario, Canada
por: Pereira, Jennifer A, et al.
Publicado: (2019)

Pet Ownership Protects Against Recurrence of Clostridioides difficile Infection
por: Redding, Laurel E, et al.
Publicado: (2020)

Clostridioides difficile Binary Toxin Binding Component Increases Virulence in a Hamster Model
por: Simpson, Morgan, et al.
Publicado: (2023)

Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
por: Olsen, Margaret A, et al.
Publicado: (2023)

A Risk Score to Predict Clostridioides difficile Infection
por: Aukes, Laurie, et al.
Publicado: (2021)

Propensity-Matched Cost of Clostridioides difficile Infection Overdiagnosis
por: Madden, Gregory R, et al.
Publicado: (2020)

2388. High-risk antibiotics associated with Clostridioides difficile infection: a national, multicenter analysis
por: Young, Eric H, et al.
Publicado: (2019)

Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection
por: Alonso, Carolyn D, et al.
Publicado: (2021)

Community-Onset Clostridioides Difficile Infection in Hospitalized Patients in The Netherlands
por: Crobach, M J T, et al.
Publicado: (2019)

Binary Toxin Expression by Clostridioides difficile Is Associated With Worse Disease
por: Young, Mary K, et al.
Publicado: (2022)

Preservation of the Innate Immune Response to Clostridioides difficile Infection in Hospitalized Immunocompromised Patients
por: Banegas, Marcela, et al.
Publicado: (2023)

Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use
por: Carlson, Travis J, et al.
Publicado: (2021)

Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
por: Hengel, Richard L, et al.
Publicado: (2020)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

Clostridioides difficile Infection Treatment and Outcome Disparities in a National Sample of United States Hospitals
por: Young, Eric H., et al.
Publicado: (2022)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
por: Johnson, Tanner M, et al.
Publicado: (2021)

92180 Prevalence of Clostridioides difficile strains found in Texas soil
por: Zeidan, Amina R., et al.
Publicado: (2021)

Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains
por: Endres, Bradley T, et al.
Publicado: (2019)

Persistent Systemic Microbial Translocation, Inflammation, and Intestinal Damage During Clostridioides difficile Infection
por: Oliva, Alessandra, et al.
Publicado: (2019)

The Impact of Infection Versus Colonization on Clostridioides difficile Environmental Contamination in Hospitalized Patients With Diarrhea
por: Warren, Bobby G, et al.
Publicado: (2022)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

Clostridioides difficile Enteritis in Patients Following Total Colectomy—a Rare but Genuine Clinical Entity
por: Ulrich, Robert J, et al.
Publicado: (2019)

Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah D, et al.
Publicado: (2022)

Fecal Transplant in Children With Clostridioides difficile Gives Sustained Reduction in Antimicrobial Resistance and Potential Pathogen Burden
por: Hourigan, Suchitra K, et al.
Publicado: (2019)

Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer
por: Cornely, Oliver A, et al.
Publicado: (2020)

Adoption and Trends in Uptake of Updated ICD-10 Codes for Clostridioides difficile—A Retrospective Observational Study
por: Deshpande, Abhishek, et al.
Publicado: (2022)

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes
por: Dubberke, Erik R, et al.
Publicado: (2022)

Clostridioides difficile Infection: Clinical Practice and Health Outcomes in 6 Large Tertiary Hospitals in Eastern Australia
por: Stewart, Adam G, et al.
Publicado: (2023)

Comparison of Different Antibiotics and the Risk for Community-Associated Clostridioides difficile Infection: A Case–Control Study
por: Miller, Aaron C, et al.
Publicado: (2023)

Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients
por: Ilett, Emma E, et al.
Publicado: (2019)

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study
por: Wilcox, Mark H, et al.
Publicado: (2019)

Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2022)

Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review
por: Bainum, Taryn B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_inhsf5svkh04gokjomobi874k4